Abstract: Three known impurities in oseltamivir phosphate bulk drug at level 0.1% (ranging from 0.05-0.1%) were detected by gradient reverse phase high performance liquid chromatography. These impurities were preliminarily identified by the mass number of the impurities. Different experiments were conducted and finally the known impurities were synthesized and characterized.
Introduction
Oseltamivir is an ester prodrug, which is rapidly and extensively hydrolysed in vivo to its active metabolite oseltamivir carboxylate, a potent and selective inhibitor of influenza virus neuraminidase 1 is considered the leading currently available antiviral to counter a serious epidemic or pandemic outbreak of influenza 2, 3 . The current concerns over avian influenza A (H5N1) have created an increased demand for this drug. Pharmaceutical counterfeiting is a well recognized global health problem with a particular impact in developing countries where drug-regulatory systems are weak or ineffective 4 . There have been many alarming reports lasting recent years of counterfeit antimalarials, antibiotics, hormones and steroids, analgesics and antipyretics, anti-asthma and anti-allergy drugs [5] [6] [7] [8] [9] [10] [11] .
Oseltamivir phosphate is a white crystalline solid with the chemical name (3R,4R,5S)-4-acetylamino-5-amino-3(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid, ethyl ester, phosphate (1:1). The chemical formula is C 16 There are several process impurities/related substances associated with the manufacture of oseltamivir phosphate. Different process related impurities have been observed with various synthetic routes and/or manufacturing processes. Six of the known oseltamivir phosphate related substances have been mentioned in International Pharmacopoeia. All these impurities are never present together while we are preparing bulk drug or preparing formulation.
The International Pharmacopoeia 12 specifies that individual impurity is not more than 0.1% and total impurity is not more than 0.7%. During the process development of oseltamivir phosphate three known impurities were identified in the analysis of different batches whose percent area ranged from 0.05-0.1% by HPLC 12 . A comprehensive study has been carried out to isolate or to prepare and characterize these impurities. To the best of our knowledge, synthesis rout of impurities is novel and not reported in literature. Due to the importance of regulatory authorities 13 all the impurities which are at the level of >0.1% must be identified and characterized.
A literature search revealed that only analytical procedure [14] [15] [16] [17] [18] is available but nobody has reported synthesis, isolation and characterization of impurities in the purified form starting from oseltamivir phosphate. The present communication involves the isolation or preparation of impurities and characterization by chromatographic and spectroscopic techniques 19 .
Experimental
The investigated samples of bulk oseltamivir phosphate were received from pharmasolve specialities (I) Pvt. Ltd. Mumbai.
High performance liquid chromatography (HPLC)
An LC method was used for monitoring the reaction of oseltamivir impurities. A shimadzu model LC2010CHT equipped with a UV detector was used. The chromatographic conditions optimized were ODS, 50×4. 
Mass spectrometry
Electrospray ionization mass spectroscopy was performed using an ion trap mass spectrometer (Model 6310 agilent). The positive and negative electrospray MS data was obtained by switching the capillary voltage between n+ 5000 and -4500V respectively.
NMR spectroscopy
The NMR experiments were performed on Bruker avance II 400 MHz. The 1H chemical shift values were reported on the δ scale in ppm, relative to TMS (δ=0.00) and the 13 C chemical shift values were reported relative to CDCl 3 (δ=77.00 ppm) and DMSO, d6 (δ=39.50 ppm) as internal standards.
1 H and 13 C experiment was run using a mixing time of 1000 ns.
FT-IR spectroscopy
The IR spectra were recorded in the solid state as KBr dispersion medium using Perkin Elmer spectrum 100 FT-IR spectrophotometer.
Synthesis of impurities

Synthesis if impurity 1 and 2
Oseltamivir base (1 g) was charged with 100 mL methanol into a double necked round bottom flask with magnetic stirrer. Methanolic sodium hydroxide was added drop wise and the reaction mass was heated very carefully and the reaction mass was refluxed at methanol boiling point. The reaction was monitored after every 1 h by HPLC. After completion of reaction the reaction mass was neutralised with dilute HCl. The HPLC analysis shown 2 peaks separately which confirm the presence of two different impurities. Both peaks were purified using preparative HPLC and marked as fraction-1 and 2 (Scheme 1). The salt was removed by preparative HPLC after desalting and the sample was kept for freeze drying. 
Synthesis of impurity 3
Oseltaivir base (1 g) was charged with 100 mL methanol into a double necked round bottom flask with megnatic stirrer. To this methanolic sodium hydroxide was added and the reaction mass was stirred at room temperature. The reaction was monitored after every 1 h by HPLC. The HPLC analysis had shown 1 peak which confirms the presence of one different impurity. This peak was purified using preparative HPLC and marked as fraction-3 (Scheme 2). After completion of reaction the reaction mass was neutralised with dilute HCl. The salt was removed by preprative HPLC after desalting the sample was kept for freeze drying. 
Results and Discussion
Structure elucidation of impurity 1(Impurity-A)
Sample was analyzed by HPLC and its purity was found to be 94.13%, molecular weight of oseltamivir phosphate impurity-A is 284.36,28 mass unit less than that of oseltamivir phosphate. The ESI mass spectrum of sample gave a protonated molecular ion at m/z 285. 
Structure elucidation of impurity 2(Impurity-B)
Sample was analyzed by HPLC and its purity was found to be 92.61%, molecular weight of oseltamivir phosphate impurity-B is 284.36,28 mass unit less than that of oseltamivir phosphate. The ESI mass spectrum of sample gave a protonated molecular ion at m/z 285.0, which is the same as oseltamivir phosphate impurity-B, IR spectrum displayed characteristic absorptions at 3419. 19 (s, 1H), 3.38 (s, 1H), 3.83-3.85 (d,1H), 3.34-3.36 (m,1H) 
Structure elucidation of impurity 3(Impurity-D)
Sample was analyzed by HPLC and its purity was found to be 97.37%, molecular weight of oseltamivir phosphate impurity-D is 298.39,14 mass unit less than that of oseltamivir phosphate. The ESI mass spectrum of sample gave a protonated molecular ion at m/z 299. Impurity 3 Scheme 4.
13 C NMR assignment of impurities 1,2 & 3 
Conclusion
This research paper describes the synthesis, isolation and structure elucidation of process related impurities in oseltamivir phosphate. The impurities was separated by reverse phase chromatographic technique, further isolated these impurities by semi preparative liquid chromatography. The isolated impurities was characterized using spectroscopic techniques. This isolated impurities was used for mass balance of oseltamivir phosphate technical material. The synthesis of impurities was also discussed in brief.
